ClinicalTrials.gg
Not yet recruitingNCT07191548LIVERMET-IREUpdated Oct 10, 2025

International Study on Treatment of Patients With Metastatic Colorectal Liver Lesions Patients With IRE

An interventional study of Irreversible Electroporation in Colorectal Adenocarcinoma Metastatic in the Liver, Liver Ablation and Liver Cancer, Adult, sponsored by Angiodynamics, Inc.. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-10.

Sponsored by Angiodynamics, Inc. · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Procedural data will be recorded from patients with liver metastases from colorectal cancer who have received at least one course of systemic chemotherapy and who have been assessed by an appropriately constituted MDT (or equivalent) as appropriate to receive irreversible electroporation.

02

Conditions studied

  • Colorectal Adenocarcinoma Metastatic in the Liver
  • Liver Ablation
  • Liver Cancer, Adult

Keywords

  • irreversible electroporation
  • liver ablation
  • metastatic liver disease
  • nanoknife
  • liver ire registry
03

In context

Carcinoma, Hepatocellular

3,648 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,061 are open to participants now.

This study's planned enrollment of 50 is close to the median of 54 across 2,618 interventional studies indexed under Carcinoma, Hepatocellular.

Browse Carcinoma, Hepatocellular studies →

Lead sponsor

Angiodynamics, Inc. is the lead sponsor of 22 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 years and over, able to provide and with histological confirmation of a diagnosis of colorectal cancer from primary tumour.
  • Liver lesions demonstrating radiological characteristics (on magnetic resonance scan) of colorectal hepatic without requirement for . In the setting of an intact liver, patients with up to four metastases ≤ 4cm in size are eligible for inclusion. In the setting of proposed resection plus ablation, up to two metastases ≤ 4cm in size. In the setting of recurrence after prior hepatectomy up to two metastases ≤ 4cm in size.
  • Eastern Co-operative Oncology Group () Score ≤ 2.
  • Rockwood Frailty Score ≤ 3.
  • Serum \< 30 µmol/L.
  • Serum creatinine \< 150 µmol/L.
  • Up to two lung metastases (\< 2cm in size permitted at enrolment).
  • Prior treatment with at least one course of systemic chemotherapy (± biologic agent) mandated. Chemotherapy protocol is not specified and is at clinician discretion.
  • Primary rectal tumour can remain in situ treated with radiotherapy/chemoradiotherapy according to tumour board recommendations. Primary colonic tumour can remain in situ.
  • No prior hepatic tumour ablation

Exclusion criteria

Exclusion Criteria:

  • Patients involved in other research studies.
  • Inability to give .
  • Patients who are pregnant.
  • Accepted exclusions to IRE from consensus criteria including:
  • count \< 50x109 U/L.
  • (INR) for blood clotting > 1.7.
  • Prior hepatic tumour ablation.

Cardiovascular fitness related exclusions:

  • History of ventricular arrhythmia.
  • Implanted pacemaker or defibrillator.
  • Congestive cardiac failure Class ≥ 3.

Tumour-related exclusions:

  • Tumour ≥ 4 cm in size.
  • Advanced multi-site cancer (any of the following): peritoneal metastases (M1c), bone metastases, > 2 lung metastases, all segment involvement multiple liver metastases.
  • Jaundice (serum > 30 µmol/L).
  • MDT/tumour recommends use of thermal ablation instead of IRE for any given lesion.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Use of NanoKnife System for ablation of metastatic colorectal lesions

    Device: Irreversible Electroporation

Interventions

  • DeviceIrreversible Electroporation

    Irreversible electroporation (IRE) is a procedure which involves the passage of short intense electrical pulses between probes to destabilize cell membranes by creating "nanopores" which leads to cell destabilisation and cell death. IRE can be used to selectively damage cancerous cells whilst sparing adjacent supporting connective tissue in vessels and bile ducts allowing a more targeted treatment compared to other types of ablation. IRE also avoids the heat-sink phenomenon which compromises the effectiveness of thermal ablation and possibly reduces the risks of biliary injury.

    Also known as: nanoknife

06

What researchers measure

Primary outcomes

  1. Target Tumour Eradication

    The percentage of target tumours successfully eradicated 6 months after the initial IRE procedure, according to RECIST and PERCIST criteria.

    Time frame: 6 months

Secondary outcomes

  1. Complications of IRE: Episode-related complications:

    All complications recorded during inpatient stay recorded using Clavien-Dindo and CCI

    Time frame: 30 days

  2. Complications of IRE: Intervention for local liver-related complications of IRE

    Intervention for local liver-related complications of IRE within 12 months of the procedure categorised as radiological, surgical or medical

    Time frame: 12 months

  3. Oncological outcomes: Local progression at site of IRE-treated lesion

    Local progression at site of IRE-treated lesion

    Time frame: 12 months

  4. Oncological Outcomes: Re-ablation and modality.

    Re-ablation and modality.

    Time frame: 12 months

  5. Oncological Outcomes: New lesions

    Appearance of new lesions in liver, lungs, peritoneum or elsewhere (other) on follow-up.

    Time frame: 12 months

  6. Oncological Outcomes: Post IRE Chemotherapy

    Any use of chemotherapy after IRE

    Time frame: 12 months

  7. Oncological Outcomes: Other liver-directed interventions

    Any further liver-directed, anti-cancer intervention including surgery and radiotherapy.

    Time frame: 12 months

  8. Oncological Outcomes: Disease-free and overall survival from time of IRE.

    Disease-free and overall survival from time of IRE.

    Time frame: 12 months

  9. Quality of life - pre procedure

    EQ-5D-5L survey

    Time frame: pre procedure up to 7 days

  10. Quality of life - 7 days follow-up

    EQ-5D-5L survey

    Time frame: 7 days

  11. Quality of life - 6 months

    EQ-5D-5L survey

    Time frame: 6 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07191548
Responsible party
Sponsor
First posted
Sep 25, 2025
Start date
Feb 2026 (estimated)
Primary completion
Feb 2028 (estimated)
Completion
Feb 2029 (estimated)
Last update
Oct 10, 2025

Study contacts

Mitchell Vanderpoll
Contact
mvanderpoll@angiodynamics.com
+44 7790921819
Ajith Siriwardena, MD FRCS
principal investigator · Manchester Royal Infirmiary

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion